The present invention relates to a novel crystalline form of 4-(5-{(lR)-l-[5-(3-chlorophenyl)isoxazol-3-yl]ethoxy}-4-methyl-4H-l ,2,4-triazol-3-yl)pyridine. Further, the present invention also relates to the use of the novel crystalline form for the treatment of gastrointestinal disorders, and pharmaceutical compositions containing it.